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Background
Heart failure (HF) remains as important chal-
lenge in cardiovascular medicine. The incidence 
increases with age reaching 10% of the human 
population after the seventh decade of life [1, 2]. 
Despite advances in HF therapy, morbidity re-
mains high regardless of HF etiology. Treatment 
is focused mainly on the reduction of symptoms; 
however, it has been shown to date that a reduc-
tion in mortality was achieved only in heart failure 
patients with reduced ejection fraction (HFrEF) 
[3]. On top of that, the group of patients with heart 
failure with preserved ejection fraction (HFpEF) 
continues to grow. 
The diastolic dysfunction, which is common 
among HFpEF patients is mainly driven by dimin-
ished left ventricle relaxation, increased volume 
and filling pressures in the left atrium that leads 
to pulmonary congestion [4, 5]. In these patients, 
treatment options are limited mainly to diuretics.
A novel conception of therapy based on creat-
ing a communication between both atria has been 
proposed recently. The left to right interatrial shunt 
enables decompression of the left atrium and thus 
may improve patient symptoms [6, 7].
There are three different devices available for 
patients with either HFrEF or HFpEF: interatrial 
shunt device (IASD, Corvia Medical Inc., Tewks-
bury, MA, USA); V-Wave shunt (V-Wave Ltd., 
Caesarea, Israel) and the Atrial Flow Regulator 
(AFR, Occlutech, Heslingborg, Sweden). The 
initial safety and efficacy have been proved for the 
first two devices in small studies [6, 7]. Atrial Flow 
Regulator is a self-expandable double-disc nitinol 
wire mesh construction allowing communication 
across the interatrial septum. The offered fenestra-
tion diameter ranges from 4 mm to 10 mm, but for 
HF patients only the 8 mm and 10 mm have the 
European CE mark. The device is fully reposition-
able and retrievable.
There are few data concerning the effective-
ness of interatrial shunting. It is reasonable to focus 
on defining clinical and hemodynamic parameters, 
thus predicting who would benefit from interatrial 
shunting. The Pomeranian atRial flOw reguLatOr 
iN conGestive hEart failuRe (PROLONGER) study 
was designed for this purpose.
Methods
Study design
The PROLONGER study (ClinicalTrials.gov 
identifier NCT04334694) is a prospective, open-
-label clinical trial aimed to define invasive and non- 
invasive parameters that could predict a positive 
response for AFR therapy among patients with HF. 
The observation period will include peri-procedural 
hospitalization and a 12 month follow-up with four con-
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Around 30 patients will be enrolled. The 
main inclusion criterion is symptomatic HF, either 
HFrEF or HFpEF. An elevated left heart filling 
pressure has to be confirmed in all eligible patients 
before the AFR procedure. Detailed inclusion and 
exclusion criteria are presented in Table 1. 
Blinding (masking)
As the PROLONGER is an open-label, single-
-arm study, both the participants and investigators 
will not be blinded to the allocated intervention.
Interventions
All eligible patients will undergo detailed 
screening using echocardiography, impedance 
cardiography (ICG) and right heart catheterization 
prior to AFR implantation.
Echocardiography. The transthoracic echo-
cardiography (TTE) examinations will be taken as 
recommended by European Society of Cardiology 
(ESC) and American Heart Association (AHA). 
Patients will be imaged in the left lateral decubitus 
position. Images will be obtained in the parasternal 
and apical chamber views. 
The echocardiography protocol consists of the 
following elements recorded with three cardiac 
cycles loop recordings:
 — Long axis view (LAX): Dimensions of left and 
right ventricles, left atrium, morphology and 
function of aortic and mitral valves;
 — Short axis view (SAX): Morphology and func-
tion of aortic and pulmonic valves; pulse 
wave Doppler in right ventricle outflow tract 
(RVOT) (assessment of acceleration time);
 — Apical 4 and 2 C plane:
• Assessment of right ventricle dimension 
right ventricle inflow tract (RVIT), right 
atrium area, left atrium volume index 
(LAVI),
• Assessment of left ventricle systolic func-
tion (ejection fraction by Simpson method 
and by speckle tracking imaging),
• Assessment of left ventricle diastolic 
function (by using mitral flow, mitral an-
nulus diastolic velocity, left atrial volume, 
tricuspid regurgitation (TR) velocity,
• Assessment of right ventricle systolic 
function by tricuspid annular plane sys-
tolic excursion (TAPSE), right ventricle 
fractional area change and speckle track-
ing imaging,
• Morphology and function of mitral valve,
• Mechanism and quantitative assessment 
of mitral regurgitation,
• Morphology and function of aortic valve,
Table 1. The inclusion and exclusion criteria in 
PROLONGER study.
Inclusion criteria
1 Age ≥ 18 years 
2 Symptomatic HF in NYHA class III or IV  
ambulatory
3 Optimal medical therapy of HF according  
to ESC guidelines for last 6 months
4 Hospitalization because of HF decompensation 
in last 12 months
5 Absence of significant valvular disease requiring 
cardiac surgery
6 Life expectancy ≥ 1 year
7 Written informed consent obtained from  
the patient
8 Left ventricular ejection fraction ≥ 15%
9 Elevated left heart filling pressures:
•	PAWP in rest > 15 mmHg or
•	PAWP > 25 mmHg during handgrip test
Exclusion criteria
1 Participation in another clinical trial in last  
30 days
2 Acute infection or sepsis
3 Severe coagulation disorder
4 Allergy to nickel or titanium
5 Severe peripheral artery disease disabling 
6MWT
6 Allergy to antiplatelet drugs, oral anticoagulation 
or heparin
7 Contraindications to transesophageal  
echocardiography
8 Pregnancy
9 ASD or presence of ASD septal occluder
10 Severe PFO with significant left to right  
shunt in rest
11 Intracardiac thrombus
12 ACS or PCI or CABG in last 6 months
13 Severe pulmonary hypertension:
•	Right atrial pressure ≥ PAWP
•	Right atrial pressure ≥ 20 mmHg
14 Planned heart transplantation
15 TIA or stroke within last 6 months
16 CRT therapy within last 6 months
HF — heart failure; NYHA — New York Heart Association;  
ESC — European Society of Cardiology; PAWP — pulmonary  
artery wedge pressure; 6MWT — six-minute walk test; ASD — atrial 
septal defect; PFO — patent foramen ovale; ACS — acute coronary 
syndrome; PCI — percutaneous coronary intervention; CABG — 
coronary artery bypass grafting; TIA — transient ischemic attack; 
CRT — cardiac resynchronization therapy
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• Morphology and function of tricuspid 
valve,
• Quantitative assessment of tricuspid re-
gurgitation;
 — Subcostal view:
• Position and flow (color Doppler) in AFR 
device, flow gradient (continuous wave 
Doppler).
The TTE examinations will be done before 
AFR and during each follow up visit.
All patients will also be imaged with trans- 
esophageal echocardiography (TEE) in standard 
views to:
 — Exclude intra-cardiac thrombus;
 — Exclude presence of patent foramen ovale 
(PFO) or atrial septal defect (ASD);
 — Assess anatomy of interatrial septum.
The TEE examinations will be done prior to 
AFR procedure and during the first follow up visit.
Impedance cardiography. All patients will 
be examined using an ICG. 
The PhysioFlow® Q-LinkTM is a noninvasive 
hemodynamic evaluation system to assess patient 
cardiovascular state using the analysis of trans-
thoracic bio-impedance signals. 
PhysioFlow System measures the change in 
impedance by injecting a high frequency alternat-
ing electrical current (66 kHz) of low magnitude 
(4.5 mA peak to peak) towards the thorax between 
two electrodes positioned on the neck and another 
two positioned on xiphoïd process. The use of 
a high frequency current eliminates the risk of 
interference with heart and brain bioelectrical 
activity. In addition, as the impedance of skin-
electrodes is very low at high frequency, tissues 
will not endure any thermal effects and patients 
feels nothing. 
Specific calculations conducted, as part of 
further analysis will be based on values obtained 
in the supine position. 
The measurement scheme will be as follows: 
the first ICG will be done 1 day prior to the AFR 
procedure. Four ICG and two ECG pre-gelled 
electrodes will be placed: two (Z1, Z2) on the left 
side of the patient’s neck, one (Z3) at the level of 
the xiphoid and the last one (Z4) just to the right 
to Z3. The ICG data will be collected continuously 
(beat by beat) for 30 min. The blood pressure will 
be taken every 10 min and stored for analysis. 
The following parameters will be measured con-
tinuously: cardiac index (CI [l/min/m2]), stroke 
volume index (SVi [mL/m2]), left cardiac work 
index (LCWi [kg∙m/m2]), contractility index (CTi), 
ventricular ejection time (VET [ms]), systemic 
vascular resistance index (SVRi [dyn∙s/cm5∙m2]), 
thoracic fluid content index (TFCi [1/kΩ∙m2]) and 
heart rate (HR [1/min]).
The values of these parameters will be record-
ed beat-to-beat. Specific calculations conducted, as 
part of further analysis, will be based on the values 
obtained in the supine position. 
The ICG examinations will be done before 
AFR and during each follow up visit.
Invasive right heart catheterization. All 
eligible patients before enrolling to the study 
will undergo a diagnostic right heart catheteriza-
tion using a Swan-Ganz catheter (SGC). After 
ultrasound-guided puncture of internal jugular or 
subclavian vein, a SGC will be introduced via the 
right ventricle to a pulmonary artery. The following 
pressure curves will be obtained in patients at rest:
 — Right atrium/upper vena cava pressure;
 — Right ventricle pressure;
 — Mean pulmonary artery pressure;
 — Pulmonary artery wedge pressure (PAWP).
Furthermore, a cardiac output (CO) will be 
measured using the thermodilution method. 
The following hemodynamic parameters will 
be calculated:
 — Cardiac index;
 — Systemic vascular resistance;
 — Pulmonary vascular resistance.
In the next step, subjects will be asked to 
perform a handgrip test for a maximal tolerated 
period of time until  fatigued. The measurement 
of PAWP and CO will then be obtained.
If a resting PAWP will be above 15 mmHg 
or exercise PAWP above 25 mmHg, patients will 
be qualified for AFR implantation. A right atrial 
pressure above 20 mmHg or exceeding PAWP 
will be the contraindication for the atrial shunting 
procedure.
 Invasive catheterization will be performed 
before AFR and during the first follow up visit.
The AFR procedure. The procedure will 
be performed under general anesthesia. A three-
dimensional TEE guided trans-septal puncture will 
be performed followed by insertion of an Amplatzer 
Stiff wire in a left upper pulmonary vein. Next, 
a 10–14 mm diameter balloon septostomy to facili-
tate AFR implantation through a 12–14 F dedicated 
delivery system. Before releasing the device, an 
invasive trans atrial gradient will be measured 
through an 8–10 mm fenestration. The left to right 
shunt and mean gradient will be confirmed in TEE. 
After releasing an AFR device, a delivery system 
will be removed and a puncture site will be sealed 
with hemostatic suture.
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The patients will be discharged during the 
following couple of days. Subjects with history 
of atrial fibrillation will continue anticoagulation 
therapy and those without atrial fibrillation will be 
treated with double antiplatelet drugs for 3 months.
Outcomes
Primary outcome measures. The primary 
outcome is clinical improvement within 12 months 
after AFR implantation defined as at least 10% in-
crease in six-minute walk test (6MWT) compared 
to baseline. 
Secondary outcomes measures. (1) Clinical 
improvement expressed in reduction of New York 
Heart Association (NYHA) class; (2) Device related 
adverse event: device migration, embolization, 
device related thrombus, shunt occlusion, or need 
for device removal.
Other outcome measures. (1) Reduction 
of PAWP at rest 30 days after AFR implantation. 
(2) Reduction of PAWP during a handgrip test 
30 days after AFR implantation. (3) Kansas City 
Cardiomyopathy Questionnaire (KCCQ-12) within 
12 months after AFR implantation. (4) Clinical 
adverse events within 12 months after AFR im-
plantation: cardiac mortality or rehospitalization 
for HF decompensation.
Correlation of echocardiographic, inva-
sive and impedance parameters with clinical 
outcome. All hemodynamic data will be analyzed 
post-hoc to test any correlation with clinical out-
come after AFR procedure.
Data collection and management
All clinical data including demographic infor-
mation, results of blood laboratory tests perfor- 
med locally will be stored for further analysis. 
Digital files containing raw data obtained from 
echocardiography and fluoroscopy will also be 
collected.
Statistical methods
Continuous data will be summarized by means 
of mean value, median, minimum, maximum, stan-
dard deviation and number of observations. Cat-
egorical data will be expressed as means of absolute 
and relative frequencies. A series of statistical tests 
including: the Shapiro-Wilk test, ANOVA, unpaired 
t-test, the Mann-Whitney U or c2 test will be done. 
Clinical adverse events will be tabulated.
Ethical considerations
A local ethics committee has approved the 
PROLONGER study protocol.
Discussion
The concept of creating an interatrial shunt 
leading to decompression of left atrium is an at-
tractive therapy for patients with HF.
Presented herein, is the PROLONGER study 
protocol. This is a single center, open label clinical 
study aimed at defining invasive and non-invasive 
clinical parameters that could predict a positive 
response for implantation of AFR. 
Three available shunt devices have been 
tested in a series of small studies to date. The 
initial results are promising; however, the ques-
tion of which population would benefit most from 
interatrial shunting has been raised.
In the AFR PRELIEVE study some, but not 
all patients showed symptoms improvement. The 
6MWT distance significantly increased only among 
HFrEF patients. The interpretation of single 
statistically significant results such as change in 
NYHA class or increase in 6MWT distance should 
be cautious, because the patient numbers were 
small. Both HFpEF and HFrEF patients presented 
reduced resting PAWP compared to baseline, 
however only in HFpEF subjects, the difference 
reached statistical significance [8].
In the present study we are going to focus 
on clinical parameters as: 6MWT test and NYHA 
functional class. 
Although the study is not designed to show device 
related adverse events, these will also be reported.
A hemodynamic profile will be assessed by an 
invasive right heart catheterization as well as using 
non-invasive impedance cardiography.
The ICG is a non-invasive diagnostic tool 
enabling reliable assessment of patients’ hemody-
namic profile [9–13].  
There are data supporting a good correlation 
between impedance diagnostics and invasive as-
sessment of cardiac output and systemic vascular 
resistance [14]. Our previous experience with this 
procedure in patients with acute myocardial infarc-
tion was recently published [15].
Unlike previously published studies, the focus 
will be to perform exercise invasive catheterization 
using a simple handgrip test instead of standard 
cyclo-ergometer. Although a handgrip test in not 
well validated, it allows a patient to perform sig-
nificant exertion.
The hemodynamic data obtained from SGC and 
ICG will be analyzed post-hoc in order to seek any 
correlation of cardiac filling pressures and cardiac 
performance with clinical improvement after the 
AFR procedure.
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The first patient enrolled to PROLONGER 
study presented substantial clinical improvement 
in the 6MWT distance, which almost doubled and 
a reduction of NYHA class. Diagnostic right heart 
catheterization revealed a significant reduction 
in PAWP, mean pulmonary artery and right atrial 
pressures [16].
A 12 month follow-up is planned with four 
control visits, which should allow assessment of 
clinical and hemodynamic responses for AFR.
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